A phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers Academic Article Article uri icon

Overview

MeSH Major

  • Anticoagulants
  • Drugs, Generic
  • Enoxaparin
  • Skin

abstract

  • Exatecan has minimal activity in advanced biliary tree cancers. Toxicity was predictable and manageable.

publication date

  • August 2005

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1097/01.coc.0000158829.63542.2c

PubMed ID

  • 16062073

Additional Document Info

start page

  • 334

end page

  • 9

volume

  • 28

number

  • 4